SPA Farma, a leading pharmaceutical company of innovative healthcare products and diagnostic tools, and Inbiomotion, proprietors of MAF Test® for identifying high risk early-stage breast cancer ...

The Scientific Group, a leader in the IVD industry, and Inbiomotion, a company commercializing its proprietary MAF Test® for identifying high risk early-stage breast cancer patients have signed an ...

A genetic biomarker-based diagnostic test developed by Inbiomotion SL to identify treatment for early-stage breast cancer could significantly improve patient survival, a study has found. Data from the ...